Discovery Of Isoxazole Analogues Of Sazetidine-A As Selective \( \pm 4\beta 2 \)-Nicotinic Acetylcholine Receptor Partial Agonists For The Treatment Of Depression

Jianhua Liu
Li Fang Yu
J. Brek Eaton
Barbara Caldarone
Katie Cavino

See next page for additional authors

Follow this and additional works at: https://scholar.barrowneuro.org/neurobiology

Recommended Citation
Liu, Jianhua; Yu, Li Fang; Eaton, J. Brek; Caldarone, Barbara; Cavino, Katie; Ruiz, Christina; Terry, Matthew; Fedolak, Allison; Wang, Daguang; Ghavami, Afshin; Lowe, David A.; Brunner, Dani; Lukas, Ronald J.; and Kozikowski, Alan P., "Discovery Of Isoxazole Analogues Of Sazetidine-A As Selective \( \pm 4\beta 2 \)-Nicotinic Acetylcholine Receptor Partial Agonists For The Treatment Of Depression" (2011). Neurobiology. 207. https://scholar.barrowneuro.org/neurobiology/207

This Article is brought to you for free and open access by Barrow - St. Joseph's Scholarly Commons. It has been accepted for inclusion in Neurobiology by an authorized administrator of Barrow - St. Joseph's Scholarly Commons. For more information, please contact molly.harrington@dignityhealth.org.
Authors
Jianhua Liu, Li Fang Yu, J. Brek Eaton, Barbara Caldarone, Katie Cavino, Christina Ruiz, Matthew Terry, Allison Fedolak, Daguang Wang, Afshin Ghavami, David A. Lowe, Dani Brunner, Ronald J. Lukas, and Alan P. Kozikowski
Discovery of Isoxazole Analogues of Sazetidine-A as Selective α4β2-Nicotinic Acetylcholine Receptor Partial Agonists for the Treatment of Depression

Jianhua Liu,† Li-Fang Yu,† J. Brek Eaton,‡ Barbara Caldarone,§ Katie Cavino,§ Christina Ruiz,§ Matthew Terry,† Allison Fedolak,§ Daguang Wang,§ Afshin Ghavami,§ David A. Lowe,§ Dani Brunner,§,‖ Ronald J. Lukas,§ and Alan P. Kozikowski*,†

†Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, United States
‡Division of Neurobiology, Barrow Neurological Institute, 350 West Thomas Road, Phoenix, Arizona 85013, United States
§PsychoGenics, Inc., 765 Old Saw Mill River Road, Tarrytown, New York 10591, United States
‖Department of Psychiatry, Columbia University, NYSPI, 1051 Riverside Drive, New York, New York 10032

ABSTRACT: Depression, a common neurological condition, is one of the leading causes of disability and suicide worldwide. Standard treatment, targeting monoamine transporters selective for the neurotransmitters serotonin and noradrenaline, is not able to help many patients that are poor responders. This study advances the development of sazetidine-A analogues that interact with α4β2 nicotinic acetylcholine receptors (nAChRs) as partial agonists and that possess favorable antidepressant profiles. The resulting compounds that are highly selective for the α4β2 subtype of nAChR over α3β4-nAChRs are partial agonists at the α4β2 subtype and have excellent antidepressant behavioral profiles as measured by the mouse forced swim test. Preliminary absorption, distribution, metabolism, excretion, and toxicity (ADMET) studies for one promising ligand revealed an excellent plasma protein binding (PPB) profile, low CYP450-related metabolism, and low cardiovascular toxicity, suggesting it is a promising lead as well as a drug candidate to be advanced through the drug discovery pipeline.

INTRODUCTION

Depression, a common neurological condition, affects approximately 151 million people globally.1 Depressed patients suffer from various symptoms daily, such as difficulty in concentrating, insomnia, and anhedonia.2 Although there is still a dispute as to whether depression represents a syndrome associated with other illnesses or a disease of its own, this question is immaterial to the fact that depression is one of the leading causes of disability and suicide worldwide.3,4 Today, most medications used to treat depression target serotoninergic and/or noradrenergic transmitter systems or inhibit monoamine oxidase to reduce the degradation of serotonin and noradrenaline.5 Some patients who take antidepressant drugs experience serious side effects, with fewer than half of patients responding well to currently available treatments.6 Clearly, there is still an urgent need to find safer and more effective drugs for treating depression.

Along with the discovery of other neurotransmitters and enzymes that relate to depression, various endeavors to find antidepressant medications based on different strategies have been pursued.5,6 Histone deacetylase (HDAC) inhibitors,7,8 κ opioid receptor antagonists,9 and N-methyl-D-aspartic acid (NMDA) receptor antagonists all show an antidepressant profile in preclinical rodent models. Although there is no consensus yet, K+ channel modulators are also believed to have potential in the treatment of depression.10 Furthermore, it is likely that nicotinic acetylcholine receptors (nAChRs) provide promising targets for the treatment of depression based on the following findings. First, some classic antidepressants, including tricyclics and selective serotonin reuptake inhibitors (SSRIs), inhibit nAChRs. Second, nicotine exhibits an antidepressant behavioral profile in animals. Third, and most interestingly, presynaptic nAChRs may modulate the release of monoamines.11

The α4β2-nAChRs are the most prevalent high-affinity nicotine-binding nAChR subtypes found in the central nervous system (CNS). Some of the known α4β2-nAChR-selective ligands exhibit antidepressant activities in depression models.12,13 The antidepressant effects of memantine,14 and even those of the tricyclic antidepressant amitriptyline,15 are abolished in the nAChR β2 subunit knockout mice that lack α4β2-nAChR.15 Moreover, the α3β4*-nAChR-mediated autonomic nicotinic signaling could contribute to the unwanted, adverse side effects observed in vivo.16,17 Therefore, highly selective α4β2-nAChR ligands over the α3β4 are regarded as promising antidepressant medications. Sazetidine-A (1) is a potent and selective agonist at the high-sensitivity (HS) isoform of α4β2 nAChRs18 and exhibits antidepressant-like effects in...
rodents (Figure 1). Although its structural simplicity, efficacy in vivo, and high potency make compound 1 a promising lead, the presence of a metabolically unstable acetylcholine group diminishes the attractiveness of this compound for further development. However, compound 1 is still useful as a starting point for the design of new ligands.20,21

Many structural modifications of compound 1 are conceivable to create more attractive compounds. However, replacement of the acetylene with other functional groups to increase metabolic stability is a logical first choice.21 Aromatic heterocycles (as in 2), for example, an isoxazole ring that is present in many bioactive compounds, are potential candidates for this purpose because of their planarity, which adds a minimum of bulk compared to the acetylcholine group. Several bioactive compounds bearing isoxazole rings have been reported by our group, such as HDAC inhibitors,22 anti-tuberculosis agents23,24 and peroxisome proliferator-activated receptor agonists.25

In this study, several analogues of compound 1 containing an isoxazole ring replacing the acetylene are reported. These compounds are all α4β2 nAChR-selective partial agonists. Some of them exhibit promising behavioral profiles in the mouse forced swim test and appear to be leads for the development of novel antidepressants. In preliminary absorption, distribution, metabolism, excretion, and toxicity (ADMET) studies, one of the active compounds was found to display a druglike profile, thereby commending it for further development. Additionally, all compounds showed very weak binding to α3β4-nAChRs, which mediate autonomic nicotinic signaling, suggesting that few if any peripheral side effects should be observed.26

Figure 1. Structure of sazetidine-A and proposed structure with a heteroaromatic ring replacing the acetylene group.

Table 1. Binding Affinities of Compounds 3–5 at Seven Rat nAChR Subtypes

<table>
<thead>
<tr>
<th>compd</th>
<th>α2β2</th>
<th>α2β4</th>
<th>α3β2</th>
<th>α3β4</th>
<th>α4β2</th>
<th>α4β4</th>
<th>α4β2*-</th>
<th>LogBB</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>0.90 ± 0.05</td>
<td>1410&lt;sup&gt;a&lt;/sup&gt;</td>
<td>16 ± 4</td>
<td>&gt;10 000</td>
<td>0.67 ± 0.20</td>
<td>182</td>
<td>1.9 ± 0.3</td>
<td>−0.93</td>
</tr>
<tr>
<td>4</td>
<td>0.32 ± 0.04</td>
<td>310</td>
<td>2.9 ± 0.5</td>
<td>6660</td>
<td>0.31 ± 0.10</td>
<td>81 ± 7</td>
<td>0.61 ± 0.10</td>
<td>−0.99</td>
</tr>
<tr>
<td>5</td>
<td>0.76 ± 0.20</td>
<td>518</td>
<td>8.4 ± 1.5</td>
<td>&gt;10 000</td>
<td>0.37 ± 0.10</td>
<td>219</td>
<td>1.8 ± 0.2</td>
<td>−0.99</td>
</tr>
<tr>
<td>nicotine&lt;sup&gt;c&lt;/sup&gt;</td>
<td>5.5</td>
<td>70</td>
<td>29</td>
<td>260</td>
<td>4.9</td>
<td>23</td>
<td>9.8</td>
<td>0.03</td>
</tr>
</tbody>
</table>

<sup>a</sup> See Experimental Section. <sup>b</sup> The asterisk means that other unidentified subunits also may be present, because membrane fractions prepared from rat forebrain contain nAChR subtypes whose subunit composition has not been precisely determined, although they have features of nAChRs containing α4 and β2 subunits. <sup>c</sup> LogBB was calculated from the following equation: LogBB = −0.0148PSA + 0.152CLogP + 0.139. <sup>d</sup> SEM values are not provided for K<sub>i</sub> values >100 nM. The binding data for nicotine are from the PDSP Assay Protocol Book (http://pdsp.med.unc.edu/).

RESULTS AND DISCUSSION

Compound 3, in which the number of carbon atoms between the pyridine ring and the terminal hydroxyl group matches that in compound 1, was synthesized first as the most likely candidate to maintain the biological activity of compound 1 (Figure 2).

Compound 3 was first assayed for [3H]epibatidine binding competition. Its K<sub>i</sub> values at seven different rat nAChR subtypes are listed in Table 1. The LogBB value was calculated and is shown in Table 1 to estimate the capability of compound 3 to cross the blood brain barrier (BBB).27,28 With the exception of α2β2-nAChRs, the compound proved selective for α4β2-nAChRs over other subtypes, with a K<sub>i</sub> value of 0.67 nM for α4β2-nAChRs. Moreover, this compound also exhibited high binding affinity at native α4β2*-nAChRs with a K<sub>i</sub> value of 1.9 nM. The selectivity for α4β2- over α3β4-nAChR was nearly 15 000-fold, suggesting that ganglionic nAChR-mediated side effects would be highly unlikely. Because nicotine has a similar affinity for α4β2*- as it does for α2β2-nAChRs, and since the expression of α2β2-nAChRs in the central nervous system is limited, high binding affinity to that subtype is unlikely to be problematic. Having passed the nAChR subtype selectivity screen, compound 3 was subjected to a broad radioligand binding screen to evaluate off-target activity at a variety of CNS neurotransmitter receptors. As shown in Table 2, compound 3 showed no significant binding (>50%) to other neurotransmitter receptors, including serotonergic, dopaminergic, and adrenergic receptors, with the exception of the K<sub>op</sub> opioid receptor in the initial screening. However, a secondary screen revealed that its K<sub>i</sub> value for the K<sub>op</sub> opioid receptor was in fact greater than 10 000 nM. Taken together, the data presented in Table 2 predict that there would be few side effects of compound 3 caused by its interaction with other neurotransmitter receptors.

The functional activity of compound 3 was determined by the 86Rb<sup>+</sup> ion flux assay<sup>30</sup> in SH-EP1-α4β2 cells (Table 3).<sup>31–33</sup> Its nanomolar EC<sub>50</sub> and low efficacy characterized compound 3 as a partial agonist of α4β2-nAChRs.

Encouraged by these findings, we pursued additional modifications of compound 3. In the case of analogues of compound 1, it is known that shortening the oligomethylen chain generally results
**Table 2. Binding Competition Efficacies of Compound 3 at Various Neurotransmitter Receptors at 10 μM**

<table>
<thead>
<tr>
<th>serotonergic receptors</th>
<th>5-HT₁A</th>
<th>5-HT₁B</th>
<th>5-HT₁D</th>
<th>5-HT₂A</th>
<th>5-HT₂B</th>
<th>5-HT₂C</th>
<th>5-HT₃A</th>
</tr>
</thead>
<tbody>
<tr>
<td>% inhibition</td>
<td>0.3</td>
<td>−9.9</td>
<td>7.1</td>
<td>4.1</td>
<td>22.2</td>
<td>17.7</td>
<td>14.6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>dopaminergic receptors</th>
<th>D1</th>
<th>D2</th>
<th>D3</th>
<th>D4</th>
<th>D5</th>
<th>BZPRc</th>
</tr>
</thead>
<tbody>
<tr>
<td>% inhibition</td>
<td>−3.3</td>
<td>19.8</td>
<td>15.3</td>
<td>19.8</td>
<td>−1.8</td>
<td>21.7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>adrenergic receptors</th>
<th>α1A</th>
<th>α1B</th>
<th>α1D</th>
<th>α2A</th>
<th>α2B</th>
<th>α2C</th>
<th>β1</th>
<th>β2</th>
<th>β3</th>
</tr>
</thead>
<tbody>
<tr>
<td>% inhibition</td>
<td>−9.5</td>
<td>−0.4</td>
<td>2.9</td>
<td>−0.5</td>
<td>10.8</td>
<td>22.0</td>
<td>−3.2</td>
<td>−1.0</td>
<td>−17.7</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>histaminergic receptors</th>
<th>H1</th>
<th>H2</th>
<th>H3</th>
<th>H4</th>
<th>M1</th>
<th>M2</th>
<th>M3</th>
<th>M4</th>
<th>M5</th>
</tr>
</thead>
<tbody>
<tr>
<td>% inhibition</td>
<td>−19.9</td>
<td>42.6</td>
<td>6.2</td>
<td>−4.4</td>
<td>2.0</td>
<td>11.4</td>
<td>−6.8</td>
<td>2.0</td>
<td>−18.9</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>muscarinic receptors</th>
<th>DAT</th>
<th>NET</th>
<th>SERT</th>
<th>α receptors</th>
</tr>
</thead>
<tbody>
<tr>
<td>% inhibition</td>
<td>−10.1</td>
<td>14.2</td>
<td>−0.6</td>
<td>α1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>α2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>opioid receptorsd</th>
<th>DOR</th>
<th>KOR</th>
<th>MOR</th>
<th>transpoteorc</th>
<th>DAT</th>
<th>NET</th>
<th>SERT</th>
<th>α receptors</th>
</tr>
</thead>
<tbody>
<tr>
<td>% inhibition</td>
<td>6.4</td>
<td>20f</td>
<td>14.2</td>
<td>−10.1</td>
<td>14.2</td>
<td>−0.6</td>
<td>25.9</td>
<td>−4.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>σ receptors</th>
<th>α1</th>
<th>α2</th>
<th>α3</th>
<th>α4</th>
<th>α5</th>
<th>α6</th>
<th>α7</th>
<th>α8</th>
<th>α9</th>
<th>α10</th>
</tr>
</thead>
</table>


<table>
<thead>
<tr>
<th>compound</th>
<th>EC₅₀ (nM)</th>
<th>efficacy (%)</th>
<th>IC₅₀ (nM)</th>
<th>efficacy (%)</th>
<th>α4/2 Kᵦ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>36</td>
<td>13</td>
<td>61</td>
<td>68</td>
<td>0.67 ± 0.20</td>
</tr>
<tr>
<td>4</td>
<td>25</td>
<td>13</td>
<td>16</td>
<td>66</td>
<td>0.31 ± 0.10</td>
</tr>
<tr>
<td>5</td>
<td>110</td>
<td>20</td>
<td>44</td>
<td>85</td>
<td>0.37 ± 0.10</td>
</tr>
<tr>
<td>(-) nicotine</td>
<td>290</td>
<td>88</td>
<td>430</td>
<td>93</td>
<td>4.9</td>
</tr>
</tbody>
</table>


**Table 3. Sensitivities and Efficacies of Ligand Agonism and Inactivation of Human α4β2-nAChR**

The indicated compounds were used in [³H]epibatidine efflux assays to define their intrinsic activities as agonists defined by their EC₅₀ values (nanomolar) and efficacies (normalized to that of a full agonist at a maximally efficacious concentration; see Experimental Section) when acting at human α4β2-nAChRs heterologously and stably expressed in transfected SH-EPI1 human epithelial cells. The compounds also were used in efflux assays to define their abilities to inactivate responses to a full agonist at its EC₅₀ concentration as defined by inactivation IC₅₀ values (nanomolar) and inhibitory efficacy (normalized to complete functional inhibition; see Experimental Section) when acting at human α4β2-nAChRs. The term “inactivation” is used because compounds may be acting to desensitize receptors and/or as competitive or noncompetitive antagonists, and further work is needed to make such a distinction. Shown for reference are Kᵦ values (nanomolar) for blockade of specific binding of [³H]epibatidine to membrane fractions prepared from (α4β2) HER cells transfected to express rat α4 and β2 subunits.

*SEM values were determined for each parameter and, although not presented here, typically are less than 15% for efficacy measures and no more than a factor of 2 for molar EC₅₀ or IC₅₀ values. Results for compounds 3, 4, and 5 are from four independent determinations. Results for nicotine are from ref 13.*

"The inhibitory effect is defined as percent inhibition of control at steady state following the addition of agonist (1 μM [³H]epibatidine) to membrane fractions prepared from (α4β2) HER cells transfected to express rat α4 and β2 subunits.

in retention of affinity and agonist efficacy, while extending the chain reduces these characteristics. Therefore, compounds 4 and 5 featuring shorter chains were synthesized. As is evident from Table 1, both of these compounds exhibit high binding affinity to α4β2-nAChRs and native α4β2*-nAChRs, with Kᵦ values in the nanomolar range, and possess high selectivity for α4β2-nAChRs over other nAChR subtypes, with the nonproblematic exception of α2β2-nAChRs. The selectivity for α4β2-over α3β4-nAChRs of compound 4 is an impressive 20,000-fold. The functional characterization reported in Table 3 shows that both compounds 4 and 5 are partial agonists at α4β2-nAChRs.

**In Vivo Behavioral Pharmacology.** To determine whether the high activity of our compounds at α4β2-nAChR would translate into antidepressant-like efficacy in a behavioral model, compounds 3–5 were investigated in the mouse forced swim test. In this assay, antidepressants decrease the amount of time mice spend immobile when forced to swim in a confined space. When our compounds were injected intraperitoneally (Figure 3), compound 5 showed the best antidepressant-like response, with a significant reduction in immobility seen at 10 mg/kg. Compound 4 was surprisingly weakly active only at 30 mg/kg. Compound 5 showed the highest level of ex vivo receptor occupancy at β2 receptors at 3 mg/kg (around 80%) compared to compounds 3 and 4, which showed approximately 60–70% occupancy at that dosage (Figure 4). The greater efficacy of compound 5 as compared to the other two compounds in the forced swim test may be related to the higher level of receptor occupancy of β2 receptors. Despite the high level of receptor occupancy observed,
Figure 3. Compounds 3 and 5 reduced immobility in the forced swim test in mice at the medium and highest dose tested. Compound 4 showed an insignificant trend at the highest dose only. The SSRI sertraline produced the expected decrease in immobility. ANOVAs: F (11 108) = 6.9, p < 0.001. *Fisher’s PLSD post hoc test: p < 0.05 versus vehicle. All drugs were injected intraperitoneally; n = 10/group.

Figure 4. Receptor occupancy studies of compounds 3–5 in mice showed a significant occupancy level. Compound 5 showed a higher receptor occupancy than compounds 3 and 4. *Mann–Whitney U: p < 0.05. All drugs were injected intraperitoneally; n = 3/group.

the poor antidepressant behavior of compound 4 in the forced swim test may indicate subtle differences between ligands that could be missed in a 3H-Rb" efflux assay, such as the in vivo elevation of cholinergic tone. As compounds 3 and 5 were both active at 3 mg/kg when administered intraperitoneally in the forced swim test, they were next tested for their antidepressant activity following oral administration. As shown in Figure 5 both compounds 3 and 5 decreased the time immobile at 10 mg/kg in the forced swim test, but 3 failed to show significant activity when tested at the 1 and 3 mg/kg level.

Preliminary ADMET Study. Encouraged by these favorable biological data, we submitted compound 3 for a preliminary ADMET test. In vitro metabolism studies with human and mouse liver microsomes at a concentration of 1 μM showed no detectable metabolism. Assays of the compound’s inhibitory potential toward nine different CYP450 enzymes also revealed no significant inhibition. Plasma protein binding (PPB) assays were conducted with both human and mouse plasma (CD-1) at 10 μM. In human plasma, only 0.4% binding was observed, while in mouse plasma the bound fraction was as high as 26%. The weak PPB translates to a high concentration of free drug in the blood, suggesting that compound 3 should easily diffuse through cell membranes and cross the BBB to reach its biological target. Cardiotoxicity associated with the inhibition of human ether-a-go-go-related gene (hERG) was also evaluated, and no obvious inhibition of hERG-related tail current was seen even at the high concentration of 10 μM (8.4% inhibition). These results suggest that compound 3 and its side-chain homologues represent promising drug candidates for further preclinical study.

Chemistry. The known starting material was first transformed to alkyne through a Sonogashira coupling reaction with ethynyltrimethylsilane, followed by deprotection with tetrabutylammonium fluoride (TBAF) to remove the trimethylsilyl (TMS) group (Scheme 1). Nitro compounds and were synthesized by monoprotection of diols and, followed by conversion of the remaining free hydroxyl groups to nitro groups through iodoses and as intermediates, respectively. Protected isoxazoles were synthesized through [3 + 2]-cycloaddition reactions of alkyne with nitrile oxides derived from the above nitro compounds and from their commercially available, tetrabutyryl-protected lower homologue. Deprotection with acid of the penultimate precursors yielded compounds 3–5 as their HCl salts.

CONCLUSION

In spite of the plethora of antidepressant drugs on the market, there is still the need to identify improved drug therapies that have a faster onset of action and provide effective treatment of refractory depression. As is now well understood, nAChRs represent promising targets in the search for new antidepressants. Based on rational drug design principles, analogues of compound 1 bearing an isoxazole ring in place of its metabolically unstable acetylene group were designed and tested. The compounds in this series were found to be highly selective α4β2-nAChR partial agonists. Compounds 3 and 5 exhibit excellent behavioral profiles in the mouse forced swim test, whether administered intraperitoneally or orally, consistent with the antidepressant-like efficacy of these analogues. Moreover, compound 3 exhibited no significant binding affinity for other neurotransmitter receptors or transporters, suggesting that it may be free of undesirable side effects associated with off-target activity. A preliminary ADMET study for the isoxazole revealed that this compound causes no pronounced CYP450 inhibition, possesses low plasma protein binding, and has low hERG inhibitory activity. The compelling activity profile shown by the α4β2-nAChR partial agonist, isoxazole 3, at both the pharmacological and in vivo levels recommend this compound and its analogues for further study in the quest for new antidepressant drug candidates.

EXPERIMENTAL SECTION

General. Proton and carbon NMR spectra were recorded on a 300 or 400 MHz spectrometer (1H frequency). NMR chemical shifts are
reported in δ (parts per million, ppm) with the δ 7.26 signal of CDCl₃ (1H NMR), δ 4.80 signal of D₂O (1H NMR), and δ 77.2 signal of CDCl₃ (13C NMR) as internal standards. ¹³C NMR spectra in D₂O were not adjusted. Optical rotation was detected on an Autopol IV automatic polarimeter. Mass spectra were acquired in the electrospray ionization (ESI) mode at an ionization potential of 70 eV with a liquid chromatography/mass spectrometry (LC-MS) MSD instrument (Hewlett-Packard). Column chromatography was performed by use of Merck silica gel (40–60 mesh). Purity of the final compounds (>98%) was established by use of an Agilent 1100 high-performance liquid chromatography (HPLC) system equipped with a Synergi 4 µm Hydro-RP 80A column, with detection at 254 (and 280) nm, using a variable-wavelength detector G1314A; flow rate = 1.4 mL/min; gradient elution over a time span of 20–29 min, from 30% MeOH/H₂O to 100% MeOH (both containing 0.05 vol % CF₃COOH). PL-HCO₃ MP-Resin, StratoSphere SPE purchased from Agilent Technologies, was used to remove the extra CF₃COOH (trifluoroacetic acid, TFA) and to transform the compound to its free amine form after HPLC purification.

General Procedure for [3 + 2] Cycloaddition To Form Isoxazoles (Method A). To a solution of nitro compound (2.0–3.0 equiv) and alkyne (1.0 equiv) in dry toluene (0.2 M in alkyne) were added phenyl isocyanate (1.0 equiv) and triethylamine (1.0 equiv). The reaction mixture was stirred at 60 °C for 24–48 h. After the reaction mixture was cooled to room temperature, it was diluted with water and stirred vigorously for 2 h. The mixture was extracted with CH₂Cl₂, dried over anhydrous Na₂SO₄, filtered, and concentrated in vacuo. The residue was purified by column chromatography with hexane/EtOAc (1:1) to give the isoxazoles in yields of 50–80%.

General Procedure for Deprotection of N-Boc Precursors To Afford Amines as Hydrochloride Salts (Method B). To a solution of N-Boc-protected precursor (1.0 equiv) in MeOH was added 2 N anhydrous HCl/ether (1 mL) under argon protection at room temperature. The mixture was stirred overnight. After the solvent was evaporated, the residue was dissolved in distilled water (about 20–30 mL), the solution was filtered over a cotton plug, and the water was removed under reduced pressure at 35 °C. Pure HCl salt was obtained after lyophilization.

Preparative HPLC Conditions (H₂O/MeCN System, Gradient A). An ACE AQ 150 × 21.2 mm column was used with UV detection at both 254 and 280 nm and a flow rate of 17.0 mL/min. The gradient was 8–100% acetonitrile in water (both containing 0.05 vol %

**Figure 5.** Compound 3 reduced immobility in the forced swim test in mice when given orally at 10 mg/kg. Immobility was slightly higher at the lowest dose. Compound 5 was efficacious at all doses tested. The SSRI sertraline produced the expected decrease in immobility. ANOVAs: F > 34.5; p < 0.001. *Fisher’s PLSD post hoc tests: p < 0.05 versus vehicle. N = 9–10/group.
CF₃COOH) in 25 min, isocratic 100% acetoni­trile for another 5 min, return to 8% acetoni­trile in the next 5 min, and final equilibration at 8% acetoniti­rile for the final 5 min.

Preparative HPLC Conditions (H₂O/MEOH System, Gradient B). An ACE AQ 150 × 21.2 mm column was used with UV detection at both 254 and 280 nm and a flow rate of 17.0 mL/min. The gradient was 8–100% MeOH in water (both containing 0.05 vol % CF₃COOH) in 25 min, isocratic 100% MeOH for another 5 min, return to 8% MeOH in the next 5 min, and final equilibration at 8% MeOH for the final 5 min.

3-(5-(5-[[1-(tert-Butyldimethylsilyloxy)-3-iodopropane (12) was obtained in a yield of 71% as a pale yellow oil. H NMR (400 MHz, CDCl₃) δ 3.66 (m, 4H), 2.47 (br s, 1H), 1.63 (m, 4H), 0.90 (s, 9H), 0.07 (s, 6H).

1-(Butyl­dimethylsilyloxy)-1-butanol (14). The same procedure was followed as for the preparation of compound 13. Crude compound 14 was obtained as a pale yellow oil and used directly in the next step without further purification.

1-(Butyl­dimethyl­silyloxy)-3-nitropropane (15). To a solution of compound 13 (300 mg, 1.0 mmol) in ether (7 mL) in a bottle wrapped with aluminum foil was added AgNO₂ (purchased from Aldrich, 170 mg, 1.1 mmol) in one portion. The mixture was stirred at room temperature for 2 days. After filtration followed by solvent removal, the crude compound 15 (174 mg, 79%) was obtained as a colorless oil and used directly in the next step without further purification. H NMR (400 MHz, CDCl₃) δ 4.50 (t, J = 6.8 Hz, 2H), 3.71 (t, J = 6.0 Hz, 2H), 2.18 (m, 2H), 0.88 (s, 9H), 0.05 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 72.8, 59.4, 30.4, 26.0, 18.4, 5.4.

1-(Butyl­dimethyl­silyloxy)-4-nitrobutane (16). The same procedure was followed as for the preparation of compound 15. Compound 16 was obtained (yield 34% over two steps) as a pale yellow oil.

3-(1-(Butyl­oxy­car­bonyl)-(S)-2-azetidinylmethoxy)-5-[(3-tert­butyl­dimethyl­silyloxy)ethyl]­isoxazol­yl]pyr­idine (17). To a solution of compound 15 (174 mg, 0.85 mmol) in dry MeOH was added LiOH.H₂O (56 mg, 1.3 mmol). The solution was stirred at room temperature for 1 h, before it was quenched with saturated NaCl solution. The mixture was filtered through a plug of celite and the filtrate was concentrated in vacuo. The crude residue was purified by chromatography with hexane/MeOH (5:1) to give the title product as a colorless solid (58 mg, 76%). H NMR (400 MHz, CDCl₃) δ 8.10 (d, J = 8.0 Hz, 2H), 7.73 (s, 1H), 7.12 (m, 1H), 4.98 (m, 2H), 4.03 (m, 2H), 3.83 (t, J = 6.8 Hz, 2H), 1.25 (m, 2H), 1.04 (s, 3H), 0.02 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 159.1, 152.6, 131.8, 121.5, 120.3, 101.2, 97.9, 72.6, 65.9, 59.9, 46.8, 28.3, 18.9, –0.3.

3-(1-(Butyl­oxy­car­bonyl)-(S)-2-azetidinylmethoxy)-5-ethyl­pyr­idine (8). To a solution of compound 17 (390 mg, 1.3 mmol) in dry THF was added LiOH.H₂O (56 mg, 1.3 mmol). The mixture was stirred at 0 °C for 1 h, before it was quenched with saturated aqueous NH₄Cl solution, and extracted with CH₂Cl₂. The organic phase was washed with saturated Na₂SO₄ solution, filtered, and concentrated in vacuo (125 mg, 64%). H NMR (300 MHz, CDCl₃) δ 8.76 (s, 1H), 7.64 (m, 1H), 4.61 (m, 1H), 3.79 (m, 1H), 3.69 (m, 1H), 2.88 (t, J = 6.8 Hz, 2H), 1.24 (s, 9H), 0.02 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 159.5, 151.5, 143.4, 138.1, 132.1, 120.3, 110.1, 97.9, 79.6, 65.7, 60.9, 46.8, 28.3, 18.9, –0.3.

3-(1-(Butyl­oxy­car­bonyl)-(S)-2-azetidinylmethoxy)-5-[[3-(tert­butyl­dimethyl­silyloxy)propyl]­isoxazol­yl]pyr­idine (19). Methods A was followed. Yield 59% (pale yellow oil); H NMR (400 MHz, CDCl₃) δ 8.47 (m, 2H), 7.59 (s, 1H), 6.56 (s, 1H), 4.53 (m, 1H), 4.39 (m, 1H), 4.16 (m, 1H), 3.89 (m, 4H), 2.92 (t, J = 6.0 Hz, 2H), 2.30 (m, 2H), 1.39 (s, 9H), 0.84 (s, 9H), 0.03 (s, 6H).

3-(1-(Butyl­oxy­car­bonyl)-(S)-2-azetidinylmethoxy)-5-[[3-(tert­butyl­dimethyl­silyloxy)propyl]­isoxazol­yl]pyr­idine (20). The same procedure was followed. Yield 89% (pale yellow oil); H NMR (300 MHz, CDCl₃) δ 8.42 (s, 1H), 8.18 (s, 1H), 7.43 (s, 1H), 6.56 (s, 1H), 4.60 (m, 1H), 4.47 (m, 1H), 4.35 (m, 1H), 4.22 (m, 1H), 4.02 (m, 1H), 3.99 (m, 1H), 3.69 (m, 3H), 3.36 (m, 1H), 2.30 (m, 2H), 1.39 (s, 9H), 0.84 (s, 9H), 0.03 (s, 6H).
(m, 1H), 2.14 (m, 2H), 1.66–1.41 (m, 6H), 1.20 (s, 9H); 1H NMR (75 MHz, CDCl3) δ 166.7, 162.1, 155.8, 139.5, 139.0, 123.7, 117.1, 100.3, 98.0, 79.3, 68.6, 61.8, 59.9, 59.8, 30.0, 28.6, 25.0, 18.9, 18.8.

In Vitro Studies. For experimental details of the [3H]epibatidine competition study please refer to the PDSP web site: http://pdsp.med.unc.edu/.

Cell Lines and Culture. Cell lines naturally or heterologously expressing specific, functional, human nAChR subtypes were used. The human clonal cell line TE671/RD naturally expresses human muscle-type α1*-nAChRs, containing α1, β1, γ1, and δ subunits, with function detectable by 86Rb+ efflux assays.30 The human neuroblastoma cell line SH-SY5Y naturally expresses autonomic α3β4*-nAChRs, containing α3, β4, probably α5, and sometimes β2 subunits, and also displays function detectable by 86Rb+ efflux assays.30 SH-SYSY cells also express homopentameric α7-nAChR; however, their function is not detected in the 86Rb+ efflux assay under the conditions used. SH-EP1 human epithelial cells stably transduced with human α4 and β2 subunits (SH-EP1-hα4β2 cells) have been established and characterized with both ion flux and radioligand binding assays.30 SH-EP1-hα4β2 cells have further been shown to express a mixture of high- and low-sensitivity α4β2/nAChRs, for which the ratio of functional expression on the cell surface can be approximated by the response to a fully efficacious dose of compound 1, which is fully efficacious at high-sensitivity α4β2/nAChR and negligibly efficacious at low-sensitivity α4β2.

TE671/RD, SH-SY5Y, and transduced SH-EP1 cell lines were maintained as low passage number (1–26 from our frozen stocks) cultures to ensure stable expression of native or heterologously expressed nAChRs as previously described.30 Cells were passaged once a week by splitting just-confluent cultures 1/300 (TE671/RD), 1/10 (SH-SY5Y), or 1/40 (transfected SH-EP1) in serum-supplemented medium to maintain log-phase growth.

86Rb+ Efflux Assays. Function of nAChR subtypes was investigated by use of an established 86Rb+ efflux assay protocol.30 The assay is specific for nAChR function under the conditions used, for example, giving identical results in the presence of 100 nM atropine to exclude possible contributions of muscarinic acetylcholine receptors. Cells harvested at confluence from 100 mm plates under a stream of fresh medium only (SH-SY5Y cells) or after mild trypsinization (Irving Scientific; for TE671/RD or transfected SH-EP1 cells) were then suspended in complete medium and evenly seeded at a density of 1.25–2 confluent 100 mm plates per 24-well plate (Falcon; ∼100–125 mg of total cell protein per well in a 500 µL volume; poly t-lysine-coated for SH-SY5Y cells). After cells adhered generally overnight, but no sooner than 4 h later, the medium was removed and replaced with 250 µL of complete medium supplemented with ∼350 000 cpm of 86Rb+ (NEN; counted at 40% efficiency by Cerenkov counting and the Packard TriCarb 1900 liquid scintillation analyzer). After at least 4 h and typically overnight, 86Rb+ efflux was measured by the “flip-plate” technique.39 Briefly, after aspiration of the bulk of 86Rb+ loading medium from each well of the “cell plate,” each well containing cells was rinsed with 2 mL of fresh 86Rb+ efflux buffer [130 mM NaCl, 5.4 mM KCl, 2 mM CaCl2, 5 mM glucose, and 50 mM M-N-(2-hydroxyethyl)piperazine-N’-2-ethanesulfonic acid (HEPES), pH 7.4] to remove extracellular 86Rb+. Following removal of residual rinse buffer by aspiration, the flip-plate technique was used again to simultaneously introduce 1.5 mL of fresh efflux buffer containing drugs of choice at indicated final concentrations from a 24-well “efflux/drug plate” into the wells of the cell plate. After a 9.5 min incubation, the solution was “flipped” back into the efflux/drug plate, and any remaining buffer in the cell plate was removed by aspiration. Ten minutes after the initiation of the first drug treatment, a second efflux/drug plate was used to reintroduce the same concentrations of drugs of choice with the addition of an ∼EC90 concentration of the full agonist carbachol for 5 min (∼EC90 concentrations were 200 µM for SH-EP1-hα4β2 cells, 2 mM for SH-SY5Y cells, and 464 µM for TE671/RD cells). The second drug treatment was then flipped back into its drug plate, and the remaining cells in the cell plate were lysed and suspended by addition of 1.5 mL of 0.1 M NaOH and 0.1% sodium dodecyl sulfate to each well. Suspensions in each well were then subjected to Cerenkov counting (Wallac Micobeta Triulus 1450; 25% efficiency) after placement of inserts (Wallac 1450-109) into each well to minimize cross-talk between wells.

For quality control and normalization purposes, the sum of 86Rb+ efflux in cell plates and efflux/drug plates was defined to confirm material balance (i.e., that the sum of 86Rb+ released into the efflux/drug plates and 86Rb+ remaining in the cell plate were the same for each well). Similarly, the sum of 86Rb+ efflux in cell plates and efflux/drug plates also determined the efficiency of 86Rb+ loading (the percentage of applied 86Rb+ actually loaded into cells). Furthermore, the sum of 86Rb+ in cell plates and the second efflux/drug plates defined the amount of intracellular 86Rb+ available at the start of the second, 5-min assay and was used to normalize nAChR function assessed.

For each experiment, in one set of control samples, total 86Rb+ efflux was assessed in the presence of a fully efficacious concentration of carbachol alone (1 mM for SH-EP1-hα4β2 and TE671/RD cells, 3 mM for SH-SYSY cells). Nonspecific 86Rb+ efflux in another set of control samples was measured either in the presence of the fully efficacious concentration of carbachol plus 100 µM mecamylamine, which gave full block of agonist-induced and spontaneous nAChR-mediated ion flux, or in the presence of efflux buffer alone. Both determinations of nonspecific efflux were equivalent. Specific efflux was then taken as the difference in control samples between total and nonspecific 86Rb+ efflux. The same approaches were used to define total, nonspecific, and specific ion flux responses in samples subjected to the second, 5-min exposure to test drug with or without carbachol at its ∼EC90 concentration. For the purpose of determining the approximate ratio of high- and low-sensitivity α4β2/nAChRs for a given experiment, a fully efficacious dose of 1 µM compound 1 was used for quality control.

Intrinsic agonist activity of test drugs was ascertained during the first 9.5 min of the initial 10 min exposure period by use of samples containing test drug only at different concentrations and was normalized, after subtraction of nonspecific efflux, to specific efflux in carbachol-treated control samples. Specific 86Rb+ efflux elicited by test drug as a percentage of specific efflux in carbachol-treated controls was the same in these samples whether measured in absolute terms or as a percentage of loaded 86Rb+. Even in samples previously giving an efflux response during the initial 10-min exposure to a partial or full agonist, residual intracellular 86Rb+ was adequate to allow assessment of nAChR function in the secondary, 5-min assay. However, care was needed to ensure that data were normalized to the amount of intracellular 86Rb+ available at the time of the assay, as absolute levels of total, nonspecific, or specific efflux varied in cells partially depleted of intracellular 86Rb+ due to action of any agonist present during the 10-min drug exposure period. That is, calculations of specific efflux as a percentage of loaded 86Rb+ were typically corrected for any variation in the electrochemical gradient of 86Rb+ created by intracellular ion depletion after the first (agonism/pretreatment) drug treatment.

Ion flux assays (n ≥ 3 separate studies for each drug and cell line combination) were fit to the Hill equation, $F = F_{max}/[1 + (X/EC_{50})^n]$, where F is the percentage of control, $F_{max}$ for EC50 (n > 0 for agonists) or 1C50 (n < 0 for antagonists) values by use of Prism 4 (GraphPad, San Diego, CA). Most ion flux data were fit by allowing maximum and minimum ion flux values to be determined by curve fitting, but in some cases, where antagonists or agonists had weak functional potency, minimum ion flux was set at 0% of control or maximum ion flux was set at 100% of control, respectively.

General Procedures for Behavioral Studies. Animals. BALB/cj male mice (8–10 weeks old at testing) were obtained from Jackson Laboratory (Bar Harbor, ME). Mice were housed four to a cage in a colony room maintained at 22 ± 2°C on a 12 h light–dark cycle. All animal experiments were conducted in accordance with the NIH Guide for Caring and Use of Laboratory Animals.
for the Care and Use of Laboratory Animals and the PsychoGenics Animal Care and Use Committee.

Drugs. Compounds 3–5 were synthesized according to procedures described in the text, and sertraline was purchased from Toronto Research Chemicals (Ontario, Canada). All compounds were dissolved in injectable water and administered by intraperitoneal (IP) injection or oral gavage (PO) in a volume of 10 mL/kg.

Mouse Forced Swim Test. Procedures were based on those previously described. Mice were individually placed into clear glass cylinders (15 cm tall × 10 cm wide, 1 L beakers) containing 23 ± 1°C water 12 cm deep (approximately 800 mL). Mice were administered vehicle, the SSRI sertraline (10 or 20 mg/kg) as a positive control, or compounds 3–5. Thirty minutes following IP or PO administration, mice were placed in the water, and the time the animal spent immobile was recorded over a 6-min trial. Immobility was defined as the postural position of floating in the water.

Statistical Analysis. Data were analyzed with analysis of variance (ANOVA) with treatment group (vehicle, sertraline, compounds 3–5) as the between-group variable and total time immobile in seconds (over the 6-min trial) as the dependent variable. Significant main effects were followed up with the post hoc Newman–Keuls test.

β2 nAChR Ex Vivo Receptor Occupancy. Compound 3, 4, and 5 (3 mg/kg) or water was administered 30 min before brain collection (the same time point as in forced swim testing) for analysis of β2 nAChR occupancy in the thalamus (for compound 3 and 5, n = 3; for compound 4, n = 4) as described before.

AUTHOR INFORMATION

Corresponding Author
*Phone +1-312-996-7577; fax +1-312-996-7107; e-mail kozikowa@uiuc.edu.

ACKNOWLEDGMENT

This research was supported by Award U19MH085193 from the National Institute of Mental Health. The Phoenix research component was also supported in part by the Barrow Neurological Foundation and was conducted in part in the Charlotte and Harold Simensky Neurochemistry of Alzheimer’s Disease Laboratory. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. We thank the PDSP program for performing binding affinity assays. We thank Dr. Werner Tucekmantel of PsychoGenics, Inc. for his assistance in proofreading the manuscript.

ABBREVIATIONS:

CNS, central nervous system; BBB, blood-brain barrier; HS, high-sensitivity; nAChR(s), nicotinic acetylcholine receptor(s); PBP, plasma protein binding; ADMET, absorption, distribution, metabolism, excretion, and toxicity; HDAC, histone deacetylases; NMDA, N-methyl-d-aspartic acid; SSRI, selective serotonin reuptake inhibitor; hERG, human ether-a-go-go-related gene

REFERENCES

11. Rabenstein, R. L.; Caldarone, B. J.; Picciotto, M. R. The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berlin) 2006, 189, 395–401.


(35) Preliminary ADMET studies were carried out by Cerep, Inc.


